| Name | Title | Contact Details |
|---|---|---|
Luke Denver |
Associate Director, Supply Chain Planning | Profile |
Maureen Secord |
Director, Clinical Supply Chain | Profile |
Sunil Joseph |
Director, Technology Business Partner, Clinical Research and Development Sciences | Profile |
Ellen Lopresti |
Chief People Officer | Profile |
Jill Donovan |
Associate Director, Talent Acquisition | Profile |
Early Bird is the first and only FDA-approved bleed detection system for peri and post-procedural monitoring of endovascular procedures.
PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
AQP - Affordable Quality Pharmaceuticals, Inc. is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We create solutions for Women´s Health and other priority such as Respiratory, Dermatology and Endocrinology. Excellence and innovation.